2023
DOI: 10.1016/j.sjbs.2023.103707
|View full text |Cite
|
Sign up to set email alerts
|

Enhanced activity of Ellagic acid in lipid nanoparticles (EA-liposomes) against Acinetobacter baumannii in immunosuppressed mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 47 publications
1
2
0
Order By: Relevance
“…The bronchoalveolar fluid (BALF) from infected mice contained greater quantities of IL-6, IL-1b, and TNF-a, which were significantly alleviated in mice treated with EA. These results support the possible implication of EA-liposomes in the treatment of A. baumannii infection, especially in immunocompromised mice [244].…”
Section: Acinetobacter Baumanniisupporting
confidence: 82%
“…The bronchoalveolar fluid (BALF) from infected mice contained greater quantities of IL-6, IL-1b, and TNF-a, which were significantly alleviated in mice treated with EA. These results support the possible implication of EA-liposomes in the treatment of A. baumannii infection, especially in immunocompromised mice [244].…”
Section: Acinetobacter Baumanniisupporting
confidence: 82%
“…Recent studies have shown that EA, is effective against A. baumannii and can be used into lipid nanoparticles. Results from an immunocompromised mouse model showed improved survival and reduced bacterial load in the lungs, indicating that EA liposomes may provide better treatment for A. baumannii infections than commonly used antibiotics [ 47 ]. Ble-González et al (2022) reported that leaves extract of Acalypha arvensis which contained EA was active against S. aureus , K. pneumoniae and P. aeruginosa [ 48 ].…”
Section: Discussionmentioning
confidence: 99%
“…Sherif et al reported that GA sub-growth-inhibitory concentrations (660–1055 μg/mL) inhibited biofilm formation (36.34–90.67 %) in a group of clinical isolates of A. baumannii [ 64 ]. Additionally, EA, both in its pure form and in a liposomal formulation at a concentration of 32 μg/mL, effectively inhibited biofilm formation by A. baumannii ATCC-19606 by 72.3 % and 60 %, respectively [ 47 ]. These discrepancies in activity may be attributed to the strain tested, as it has been previously established that the anti-biofilm activity of a compound can vary among different bacteria [ 64 ].…”
Section: Discussionmentioning
confidence: 99%